Last week, Liana Moussatos of Wedbush released a report highlighting a list of upcoming catalysts for biopharmaceutical companies. Specifically, she noted forthcoming events …
In a research report published Tuesday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on XOMA Corp (NASDAQ:XOMA) with a price target of $17, after …
XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, announced XOMA 358, a fully human allosteric monoclonal antibody that reduces both …
Recently, various executives have taken part in insider selling activity for the stocks of Apple Inc. (NASDAQ:AAPL), XOMA Corp (NASDAQ:XOMA), Geron Corporation (NASDAQ:GERN), and Glu …
In a research report published Thursday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on XOMA Corp (NASDAQ:XOMA) with a $17 price target, after …
XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the gevokizumab Phase 3 EYEGUARD-B study, sponsored by …
Wedbush’s healthcare analyst Liana Moussatos came out with her views on XOMA Corp (NASDAQ:XOMA), after the company reported its fourth-quarter results, posting revenues of $4.3/$18.
Roth Capital analyst Ed Arce reiterated a Buy rating on Xoma (NASDAQ:XOMA) with a $9 price target, which represents a potential upside of 127% …
In a research report sent to investors today, Roth Capital analyst Ed Arce reiterated a Buy rating on Xoma (NASDAQ:XOMA) with a $9 …
In a research report sent to investors today, Roth Capital analyst Ed Arce assumed coverage on Xoma (NASDAQ:XOMA) shares with a Buy rating and a $9.00 price …
